Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis (Q34250162)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24279994%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

case report

0 references

title

Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24279994%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24279994%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

6

Ian Judson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24279994%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

4

Khin Thway

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24279994%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Juan Martin-Liberal

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24279994%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Heather McCarty

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24279994%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Christina Messiou

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24279994%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

26 November 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24279994%20AND%20SRC:MED&resulttype=core&format=json

Clinical Sarcoma Research

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24279994%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24279994%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24279994%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24279994%20AND%20SRC:MED&resulttype=core&format=json

Antiangiogenic approach in soft-tissue sarcomas.

1 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176486

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176486

Antiangiogenic treatments and mechanisms of action in renal cell carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176486

Activity of Sorafenib against desmoid tumor/deep fibromatosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176486

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176486

Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176486

Multimodality treatment of mesenteric desmoid tumours

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176486

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176486

Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176486

High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176486

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176486

Imatinib mesylate--a new oral targeted therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176486

Platelet-derived growth factor receptors: a therapeutic target in solid tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176486

Surgical management of intra-abdominal desmoid tumours.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176486

Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176486

Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder

6 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F2045-3329-3-13

Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F2045-3329-3-13

The treatment of desmoid tumors: a stepwise clinical approach

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4176486

Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade

28 October 2018

1 reference

12 December 2020

Expression of vascular endothelial growth factor in thoracic sarcomas

1 reference

12 December 2020

Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma

1 reference

12 December 2020

Desmoid fibromatosis is a clonal process

1 reference

12 December 2020

Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma

1 reference

12 December 2020

Identifiers

DOI

10.1186/2045-3329-3-13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24279994%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

1 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24279994%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

PubMed publication ID

24279994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24279994%20AND%20SRC:MED&resulttype=core&format=json